Opus Genetics

Opus Genetics

Opus Genetics was founded in 2018 by Ben Yerxa, a biotech executive who previously led the Foundation Fighting Blindness's venture arm. The firm emerged from a structural gap: promising gene therapy candidates for inherited retinal diseases (IRDs) often stalled after early clinical data because the patient populations numbered in the hundreds, not the tens of thousands, making them non-commercial for large developers. Opus acquires these deprioritized assets from academic centers and biotechs, funds pivotal trials, and aims to move them toward FDA approval. The firm's initial pipeline concentrated on mutations in genes like LCA5, RDH12, and BEST1 — each representing a genetically defined, ultrarare form of childhood blindness. The firm's strategy is built entirely around direct clinical development, not fund-of-funds or SPV structures. Opus in-licenses gene therapy candidates — administered via adeno-associated virus (AAV) vectors — that have demonstrated early safety signals. It then finances and manages the multi-center clinical trials required for regulatory submission. Confirmed programs include gene therapies targeting Leber congenital amaurosis (LCA) linked to LCA5 mutations and retinal dystrophy caused by RDH12 mutations, both of which have entered clinical-stage testing in the United States. Geographic reach is primarily North America, with trial sites at specialized ophthalmology research hospitals. The model relies on a small internal team making high-conviction, single-asset investments rather than portfolio diversification. Opus operates with a lean team of gene therapy specialists and clinical operations experts, helmed by Yerxa. The company has not publicly disclosed total capital raised or current AUM, operating instead via discrete financing rounds for clinical milestones. The firm maintains a relationship with the Foundation Fighting Blindness and its associated clinical research network, which aids in patient identification for ultrarare disease trials. In November 2021, Opus merged with another IRD-focused gene therapy developer, Opsis Therapeutics, in an all-stock transaction that combined the companies' pipelines and retained Yerxa as CEO of the combined entity (per the firm, November 2021). Opus Genetics' structural differentiator is its focus on the 'nobody's buying' asset. While gene therapy platforms at larger biotechs require billion-dollar market estimates to merit investment, Opus identifies single-disease programs with clinical proof-of-concept and complete regulatory path to approval, where the acquirer economics exist only at the asset level. Its operating model depends on eventual handoff to a commercial-stage partner, meaning the firm itself rarely builds sales forces. This positions Opus as a translational bridge between academic discovery and commercial gene therapy infrastructure, a function that few capital allocators replicate systematically.